Last reviewed · How we verify
Influenza Fluzone vaccine
Fluzone is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against circulating influenza virus strains.
Fluzone is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains. Used for Prevention of seasonal influenza in adults and children ≥6 months of age.
At a glance
| Generic name | Influenza Fluzone vaccine |
|---|---|
| Sponsor | La Jolla Institute for Immunology |
| Drug class | inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) influenza virus particles or recombinant viral antigens that trigger both humoral and cellular immune responses. Upon vaccination, B cells produce strain-specific antibodies that neutralize circulating influenza viruses, while T cells develop memory responses to provide broader protection. This prevents or reduces the severity of influenza infection when vaccinated individuals encounter wild-type virus.
Approved indications
- Prevention of influenza A and B in adults and children ≥6 months of age
Common side effects
- Injection site soreness, redness, or swelling
- Myalgia (muscle aches)
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (PHASE1)
- A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults (PHASE3)
- Opioid, HIV and Immune System (PHASE4)
- Screening for LID Clinical Studies Unit Healthy Volunteer Protocols
- A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above (PHASE2)
- BPL-1357 Against H1N1 Influenza Virus Challenge (PHASE2)
- A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (PHASE1)
- Vaccine Pandemic Preparedness Through Airway Immunology Characterization (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Influenza Fluzone vaccine CI brief — competitive landscape report
- Influenza Fluzone vaccine updates RSS · CI watch RSS
- La Jolla Institute for Immunology portfolio CI